|
http://www.streetinsider.com/Analyst+Comments/Canaccord+Genu… Kursziel : 6$ Canaccord Genuity maintains a 'Buy' on Cytokinetics (NASDAQ: CYTK), PT $6. Canaccord analyst says, "CK357 Phase 2 ALS efficacy data shows promise of real clinical benefit in ALS. We think CK357 has a strong mechanistic rationale in ALS and muscle-wasting diseases, and very promising new Phase 2 efficacy data. We think CYTK’s partner Amgen will continue to advance Phase 2 omecamtiv in heart failure trials in 2011. Our $6 price target is based on a pNPV analysis." For more ratings news on Cytokinetics click here and for the rating history of Cytokinetics click here. Shares of Cytokinetics closed at $2.93 yesterday, with a 52 week range of $2.03-$3.80. |
|
| aus der Diskussion: | ALS - Biotech machts möglich? |
| Autor (Datum des Eintrages): | Karl79 (13.12.10 17:52:55) |
| Beitrag: | 2 von 9 (ID:40701965) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |